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Abstract 
Tissue-type plasminogen activator (tPA) is the only treatment for ischemic stroke. However, tPA 
could induce the intracranial hemorrhage (ICH), which is the main cause of death in ischemic 
stroke patient after tPA treatment. At present, there is no treatment strategy to ameliorate 
tPA-induced brain injury after ischemia. Therefore, we investigated the effect of pre-treated 
isoflurane, which is a volatile anesthetic and has beneficial effects on neurological dysfunction, brain 
edema and infarct volume in ischemic stroke model. In this study, we used oxygen/glucose 
deprivation and reperfusion (OGD/R) condition to mimic an ischemic stroke in vitro. Matrix 
metalloproteinases (MMP) activity was measured in endothelial cell media. Also, neuronal cell 
culture was performed to investigate the effect of pretreated isoflurane on the neuronal cell 
survival after tPA-induced injury during OGD/R. Isoflurane pretreatment prevented tPA-induced 
MMP-2 and MMP-9 activity and suppressed tPA-triggered LRP/NF-κB/Cox-2 signaling after 
OGD/R. Neuronal cells, incubated with endothelial cell conditioned medium (EC-CM) after tPA + 
OGD/R, showed upregulation of pro-apoptotic molecules. However, neurons incubated with 
isoflurane-pretreated EC-CM showed increased anti-apoptotic molecules. Our findings suggest 
that isoflurane pretreatment could attenuate tPA-exaggerated brain ischemic injury, by reducing 
tPA-induced LRP/NF-κB/Cox-2 in endothelial cells, endothelial MMP-2 and MMP-9 activation, and 
subsequent pro-apoptotic molecule in neurons after OGD/R. 
Key words: Tissue-type plasminogen activator, isoflurane, oxygen/glucose deprivation, endothelial cell, matrix 
metalloproteinase, neuronal cell. 
Introduction 
Tissue-type plasminogen activator (tPA) is a 
thrombolytic agent used for the treatment of ischemic 
stroke within 3 hours of onset [1, 2]. It is useful to 
dissolve the blood clot but this effect also leads to 
intracranial hemorrhage (ICH) in stroke patients [3]. 
Many clinical and experimental studies have proven 
that ICH after tPA treatment closely correlates with 
blood brain barrier (BBB) breakdown and matrix 
metalloproteinases (MMPs) activation in the brain, 
which is involved in aggravation of infarction, 
morbidity, and mortality [4-6]. MMPs play an 
essential role in tissue remodeling in normal 
conditions; however, in pathological conditions, 
MMPs are related to the degradation of the BBB [4]. In 
addition, dysfunction of MMPs results in interruption 
of cell to cell or cell to matrix homeostasis for cell 
survival through the degradation of major 
neurovascular substrates [7]. Especially, it is reported 
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that MMP-9 induces neuronal cell death directly by 
disturbing cell-to-matrix communication [7, 8]. 
Isoflurane is a volatile anesthetic used clinically 
[1]. Many experimental studies have demonstrated 
that isoflurane provides protective effects in many 
organs after ischemic reperfusion injury [8-10]. 
Isoflurane pretreatment reduced neurological deficits, 
brain edema, and infarction volume in ischemic 
animal model [11]. Furthermore, isoflurane 
preconditioning attenuates inflammation and injury 
by decreasing pro-apoptotic factors and increasing 
anti-apoptotic factors [12]. Although many 
experimental evidences have proved that isoflurane 
exerts the prevention of ischemic brain injury, 
cerebral vascular protection and suppression of brain 
inflammation [13], it is unknown whether isoflurane 
treatment may have protective effects in tPA-induced 
brain injury in cerebral ischemia. In this study, we 
investigated the effect of isoflurane pretreatment on 
tPA-induced cerebral endothelial cell damage and 
activation of MMPs from endothelial cells after 
oxygen and glucose deprivation/reperfusion 
(OGD/R). We revealed that isoflurane pretreatment 
could affect neuronal cell survival against 
tPA-induced MMPs activation after OGD/R. 
Materials and Methods 
The bEnd.3 Cell culture 
Murine brain endothelial cell line, bEnd.3, was 
purchased from American Type Culture Collection 
(Manassas, VA, USA). The bEnd.3 cells were cultured 
with Dulbecco’s Modified Eagle’s Medium high 
glucose (DMEM, Hyclone™, GE Healthcare Life 
Sciences, Logan, UT, USA), adding 10% fetal bovine 
serum (FBS, GE Healthcare Life Sciences) and 1% 
penicillin-streptomycin solution (Thermo Scientific). 
The cells were incubated at 37°C in a humid 
atmosphere in the presence of 5% CO2.  
Oxygen and glucose deprivation (OGD) 
Mouse Endothelial cells were seeded in 100 mm 
cell culture dish and incubated in an incubator which 
conditioned with an atmosphere of 5% CO2 and 95% 
N2. Before oxygen and glucose deprivation, the 
culture medium was discarded, washed with 
phosphate buffer saline (PBS). Endothelial cells were 
placed in an anaerobic chamber (tension = 0.1%) 
(Forma Scientific, Inc., Marietta, GA, USA) and PBS 
was washed away and changed to deoxygenated 
glucose-free balanced salt solution (BSS). Cells were 
exposed to OGD conditionduring6 hours. After OGD, 
BSS solution was discarded and changed into DMEM 
cultured media and cells were transferred to a CO2 
incubator for 3 hours. After reperfusion, cells and 
supernatants were collected and stored at - 80°C. The 
bEnd.3 cells were treated with the concentration of 
tPA (20µg/mL, Actilyse®; BoehringerIngelheim, 
Ingelheim am Rhein, Germany) during one hour after 
OGD. Isoflurane (Hana Pharm Co., Ltd, Hwa-Sung, 
South Korea) (10mM) stock solution was made 130ml 
isoflurane into 103ml of DMEM high glucose serum 
free media as following previous study [14]. The 
concentration of isoflurane stock solution was 
confirmed by gas chromatography. One hour before 
OGD, Endothelial cells were treated isoflurane 
(0.1mM). The receptor associated protein (RAP) (200 
nM), an antagonist for ligand interaction with LRP, 
and MG-132 (10 µM), a proteasome inhibitor and 
NF-κB inhibitor, were treated for 1 hour before 
OGD/R injury (Figure 1A). 
Cell viability assay 
Cell viability was assessed by a WST assay 
(EZ-CYTOX, DAEILLAB SERVICE, Seoul, South 
Korea). The bEnd3 endothelial cells were seeded in 
96-well plates at a density 2×105cells in 100 µl of 
DMEM culture medium per well. After pretreatment 
isoflurane and OGD/R, WST was added 10 µl per 
well. After 1 hour 30 min incubation at 37°C in the 
CO2 incubator, it was analyzed using VERSASA max 
microplate reader (Moelcular Devices, Sunnyvale, 
CA, USA) at a wavelength 450nm.  
The Neuro-2A Cell culture 
Murine neuronal cell line, Neuro-2A, was 
cultured in DMEM high glucose cultured media, 
supplemented with 10% fetal bovine serum (GE 
Healthcare Life Sciences) and 1% 
penicillin-streptomycin solution (Thermo Scientific). 
Neuro-2A cells were incubated at 37°C in a humid 
atmosphere in the presence of 5% CO2. To examine 
effects of endothelial cell-released factor on neuronal 
cells, neuronal cells were incubated with endothelial 
cell conditioned medium (EC-CM) which collected 
from endothelial cell culture after OGD/R.  
Western blot analysis 
The endothelial cells were lysate with a T-PER® 
Tissue Protein Extraction Reagent (Thermo Scientific) 
adding HaltTM protease & Phosphatase inhibitor 
cocktail (1:100, Thermo Scientific). Cells were 
centrifuged at 13000rpm at 4°C for 20 min. Pierce® 
BCA protein assay kit was used for detecting 
concentration of protein as followed manufacture’s 
protocol (Thermo Scientific). Samples were mixed 
with 5× sample buffer (BIOSESANG, INC. Seongnam, 
South Korea) and boiled at 95°C for 5 min. Proteins 
were transferred to polyvinylidene difluoride 
membranes (PVDF, Millipore, Bedford, MA, USA). 
After blocking with 5% bovine serum albumin (BSA), 
membranes were incubated with the anti-LRP (1:500, 
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Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-NF-κB p65 (1:500, Santa Cruz Biotechnology), 
anti-Cox-2 (1:500, Santa Cruz Biotechnology), anti-Bax 
(1:1000, Merck Millipore, Bedford, MA, USA), 
anti-Bcl-2 (1:1000, Abcam, Cambridge, UK) primary 
antibodies respectively. Horseradish peroxidase- 
conjugated anti-goat, anti-mouse, or anti-rabbit IgG 
reagents (1:5000) were used as secondary antibodies. 
The β-actin (1:5000, Santa Cruz Biotechnology) was 
used as an internal control. The bands were visualized 
with enhanced chemiluminescence reagents (ECL 
Plus; Amersham Biosciences, Piscataway, NJ, USA) 
under the LAS 4000 program (GE Healthcare, 
Pittsburgh, PA, USA).  
Immunocytochemistry 
Brain endothelial cells were fixed with 4% 
paraformaldehyde and washed with PBS for three 
times. Samples were blocked with 5% BSA for 1 hour 
at room temperature. Immunolabelling was 
performed with anti-NF-κB p65 (1:100, Santa Cruz 
Biotechnology) overnight at 4°C. After washing with 
PBS for 3 times, cells were incubated with 
Rhodamine-conjugated anti-rabbit IgG (1:1000, 
Jackson ImmunoResearch) at room temperature for 1 
hour. After washing with PBS for 3 times, samples 
were mounted with Vectashield with 4’, 6-diamidino- 
2-phenylindole (DAPI) (Vector Laboratories, Inc., 
Burlingame, CA, USA). Endothelial cells were 
observed under LSM700 confocal microscope (Carl 
Zeiss, Thornwood, NY, USA). 
MMP-2 and -9 activity assay 
Active form of MMP-2 and MMP-9 in 
endothelial cell media was measured by using Biotrak 
Activity Assay system from Amersham Biosciences 
(Piscataway, NJ, USA). All procedures were followed 
by the manufacturer’s protocol. Each sample was 
added into wells and incubated overnight for 
immunoreactivity at 4°C. For detection active- form of 
MMP-2 or MMP-9, detection enzyme was added and 
incubated for 1 hour at 37°C according to the protocol. 
The parameter was estimated in each well using an 
automatic ELISA reader at 450 nm.  
Statistical analysis 
Data are expressed as the means± standard error 
of the mean (SEMs). Statistical comparisons among 
groups were assessed with a one way ANOVA 
followed by a Turkey post hoc test using Prism version 
6.0. Statistical significance between groups was 
considered to be present at *p< 0.05, **p< 0.01, *** p< 
0.001 
 
 
Figure 1. Experimental procedure and measurement of cell viability. (A) It presents the diagram of experimental procedure. (B) Endothelial cells, after 
OGD/R injury, showed a reduction in cell viability (74.4%), compared with that of the control (100%); moreover, tPA treatment resulted in lower cell viability (51.8%) 
compared to that of only OGD/R-injured cells. After testing different concentrations of isoflurane, 0.1mM isoflurane treatment was shown to restore decreased cell 
viability up to 72.5%. (C) Under normoxic conditions, there were no significant differences in cell viability except for a modest reduction at 1mM isoflurane 
(81.4%).*p< 0.05,**p< 0.01, ***p< 0.001, the one-way ANOVA (means ± SEM, n = 5). 
Int. J. Med. Sci. 2017, Vol. 14 
 
 
http://www.medsci.org 
428 
Results 
Preconditioning with 0.1mM isoflurane 
increased cell viability after tPA-induced injury 
during OGD/R. 
To examine the cell viability of endothelial cells 
after tPA treatment under conditions of OGD/R, cell 
viability assays were performed under different 
concentration of isoflurane (Figure 1B, n=5). Cell 
viability decreased after OGD/R injury; however, tPA 
treatment resulted in significantly lower cell viability 
compared to that of the experimental control (OGD/R 
group). Isoflurane pre-treatment increased the 
viability of tPA-treated endothelial cells after OGD/R 
injury. After preconditioning with 0.1 mM isoflurane, 
the cell viability was higher than that in the 
tPA-treated group after OGD/R injury. Among four 
concentrations of isoflurane, preconditioning with 0.1 
mM isoflurane resulted in the highest cell viability; 
therefore, we conducted subsequent experiments 
using 0.1mM isoflurane. In normoxic conditions, cell 
viabilities after preconditioning with 0.05-0.5 mM 
isoflurane were not changed, however, that with 1 
mM isoflurane pretreatment decreased compared to 
that of the control (Figure 1C, n=5). 
MMP-2 and MMP-9 activities were reduced 
after isoflurane pretreatment. 
To demonstrate that treatment of tPA induces 
MMP-2 and MMP-9 activation after OGD/R injury, 
we measured MMP-2 and MMP-9 activities in 
endothelial cell conditioned medium (EC-CM) (Figure 
2). Our results demonstrated that a significant 
increase of MMP-2 activity in OGD/R + tPA-treated 
EC-CM was observed, however, isoflurane 
pretreatment efficiently inhibited MMP-2 activation in 
EC-CM despite tPA and OGD/R injuries (Figure 2A, 
n=3, *** p< 0.001 vs OGD/R + tPA group). MMP-9 
activation was also measured by the same method. 
Activated MMP-9 level was significantly enhanced 
after tPA treatment and OGD/R insult, whereas 
MMP-9 activation was attenuated by isoflurane 
pretreatment in EC-CM (Figure 2B, n=6, *** p< 0.001 
vs OGD/R + tPA group). Our results revealed that 
isoflurane inhibited the MMP-2 and MMP-9 activities 
after tPA treatment under conditions of OGD/R. 
These results indicated that isoflurane has an 
important role in the suppression of MMP activation 
after tPA-induced injury under OGD/R. 
LRP/NF-κB/Cox-2 signaling pathway was 
inhibited by isoflurane pretreatment. 
To examine the protective mechanism of 
isoflurane pretreatment against tPA-induced injury in 
endothelial cells during OGD/R, we performed 
western blot analysis and immunofluorescent staining 
(Figure 3). It is known that ischemic stress increases 
LRP signaling [4], therefore, we first assessed LRP 
protein levels by western blotting. Based on our 
results, LRP expression was slightly increased after 
OGD/R injury, but not by tPA itself (Figure 3B, n=3). 
Preconditioning with isoflurane considerably reduced 
LRP levels, compared to those of the OGD/R group 
and OGD/R + tPA group (Figure 3B). 
 
 
Figure 2. Reduction of tPA-induced MMP-2 and MMP-9 activations by isoflurane pretreatment (A) The level of active MMP-2 was evaluated using an 
activity assay kit. Isoflurane pretreatment blocked MMP-2 activation by tPA during OGD/R conditions. (B) Increased MMP-9 activation in the tPA-treated group after 
OGD/R, was significantly reduced in the isoflurane-pretreated group. ***p< 0.001 vs. OGD/R + tPA group, the one-way ANOVA (means ± SEM, active MMP-2 
(ng/mL) (n=3),active MMP-9 (ng/mL) (n=6)) 
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Figure 3.Inhibition of tPA-induced activation of LRP/NF-κB/Cox-2 signaling pathways in endothelial cells after isoflurane pretreatment.(A) To 
measure protein expression of LRP, NF-κB p65, and Cox-2, we performed western blot analysis; representative data are shown. (B) LRP protein expression in the 
OGD/R and OGD/R + tPA-treated group was strongly increased compared to that of the control. LRP levels were attenuated after pretreatment with isoflurane after 
tPA and OGD/R injury. (C) The relative protein expression of NF-κB p65 in the OGD/R and OGD/R + tPA-treated group showed a significant increase; however, 
isoflurane pretreatment efficiently reduced NF-κB p65 protein levels. (D) NF-κB p65 expression in the nucleus of endothelial cells were highly detected after tPA and 
OGD/R insults, however, isoflurane pretreatment efficiently reduced the expression of NF-κB p65. (E) Cox-2 protein levels in the isoflurane-pretreated group were 
slightly decreased compared with those of the OGD/R + tPA-treated group. *p< 0.05, **p< 0.01, ***p< 0.001, the one-way ANOVA (means ± SEM, Relative optical 
density (OD) of LRP, NF-κB p65, and Cox-2 (n=3)) 
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To study the role of isoflurane in OGD/R + 
tPA-induced nuclear factor-kappa B (NF-κB) 
signaling, we measured NF-κB p65, a marker of 
NF-κB activation. We observed that tPA alone did not 
increase NF-κB p65 protein levels; however, 
combining tPA treatment with OGD/R injury 
upregulated NF-κB p65. Isoflurane pretreatment 
significantly abolished tPA-activated NF-κBp65 with 
conditions of OGD/R (Figure 3A, 3C, n=3). In 
addition, we assessed NF-κB p65 expression level in 
the nucleus by immunofluorescent staining. In the 
control group, NF-κB p65 expressions were not easily 
detected in the nucleus of endothelial cells, however, 
OGD/Rand OGD/R and tPA treatment increased 
NF-κB p65 level in the nucleus. These apparent 
expression of NF-κB p65 was abolished after 
preconditioning of isoflurane (Figure 3D). 
We next investigated the level of 
cyclooxygenase-2 (Cox-2), which is known to be 
controlled by NF-κB and associated with mediating 
the inflammatory processes [15]. We found that Cox-2 
protein level was upregulated after tPA treatment in 
endothelial cells with OGD/R; however, isoflurane 
pretreatment suppressed expression of Cox-2 (Figure 
3A, 3E, n=3).  
These findings suggested that OGD/R and 
tPA-induced LRP/NF-κB/Cox-2 pathway was 
inhibited by isoflurane pretreatment. 
The NF-κB/Cox-2 signaling pathway was 
downregulated by inhibitors, RAP or MG-132 
To demonstrate if inhibition of LRP and NF-κB 
signaling pathway using RAP or MG-132 could exert 
the protective effects as same as isoflurane treatment 
on tPA-induced cell injury during OGD/R, RAP and 
MG-132 were applied 1 hour before OGD. We used 
RAP to investigate LRP role in OGD/R + tPA 
treatment. Our results showed that upregulated 
NF-κB p65 by OGD/R + tPA was efficiently 
downregulated by RAP (Figure 4A, n=3). In addition, 
a semi-quantitative graph indicated that co-treatment 
with isoflurane and RAP also inhibited the expression 
of NF-κB p65 induced by tPA and OGD/R, but did 
not have any synergistic effects (Figure 4A, 4B, n=3). 
 
 
Figure 4. Isoflurane, RAP, or MG-132 treatment inhibited LRP/NF-κB/Cox-2 pathway and MMP-2 and MMP-9 activities. (A and B) Isoflurane 
pretreatment significantly reduced NF-κB expression in the tPA and OGD/R condition; RAP and isoflurane + RAP treatment also reduced NF-κB p65 in the tPA and 
OGD/R condition. (C, D, and E) Isoflurane pretreatment significantly reduced NF-κB and Cox-2 expression in the tPA and OGD/R condition; MG-132 and isoflurane 
+ MG-132 treatment reduced NF-κB p65 and Cox-2 in the tPA and OGD/R condition. To measure the activity of MMP-2 and MMP-9 after treatment with RAP or 
MG-132, we performed an activity assay. (F and G) Isoflurane pretreatment significantly reduced the activities of MMP-2 and MMP-9 under tPA and OGD/R condition. 
RAP and isoflurane + RAP treatment reduced the activities of MMP-2 and MMP-9 in the tPA and OGD/R condition. (H and I) MG-132and isoflurane + MG-132 
treatment reduced the activities of MMP-2 and MMP-9 in the tPA and OGD/R condition. *p< 0.05, **p< 0.01, ***p< 0.001, the one-way ANOVA (means ± SEM, OD 
of NF-κB, and Cox-2 (n=3), Active MMP-2 (ng/mL) (n=3), Active MMP-9 (ng/mL) (n=3-4)) 
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To elucidate the involvement of NF-κB p65, we 
treated MG-132, which is a proteasome inhibitor that 
blocks NF-κB translocation to the nucleus [4, 16], and 
examined NF-κB p65 and Cox-2 levels by western 
blotting. Based on our results, NF-κB p65 expression 
was significantly blocked after treated with MG-132 
and co-treatment with isoflurane and MG-132 (Figure 
4C, 4D, n=3). Furthermore, MG-132 treatment and 
combination of isoflurane and MG-132 significantly 
abolished Cox-2 expression in tPA-treated endothelial 
cells after OGD/R without any synergistic effect 
(Figure 4C, 4E, n=3). 
Based on these findings, OGD/R + tPA-induced 
NF-κB/Cox-2 signals were hampered by isoflurane, 
as well as by the inhibition of LRP or NF-κB, however, 
isoflurane did not have any synergistic effect with the 
inhibition of LRP or NF-κB. 
tPA-induced MMP-2 and MMP-9 activities 
were reduced by RAP or MG-132. 
The activities of MMP-2 and MMP-9 also were 
measured after treatment with RAP or 
isoflurane/RAP co-treatment. We observed that 
MMP-2 and MMP-9 activities were efficiently 
decreased when RAP or isoflurane + RAP was treated 
in endothelial cells (Figure 4F, n=3 and 4G, n=3-4). 
Next, we measured active MMP-2 and MMP-9 levels 
after treatment with MG-132 or isoflurane + MG-132 
co-treatment, and showed that these enzymes were 
considerably inhibited, compared with activities of 
the tPA and OGD/R-treated group (Figure 4H, n=3 
and 4I, n=3-4). These results suggested that OGD/R + 
tPA-induced MMP-2 and MMP-9 activities were 
inhibited by isoflurane, as well as by the inhibition of 
LRP or NF-κB in endothelial cells after OGD/R. 
However, isoflurane did not have any synergistic 
effect with the inhibition of LRP or NF-κB. 
Pro-apoptotic Bax was suppressed after 
incubation with isoflurane-pretreated 
endothelial cell conditioned medium.  
To examine whether pretreated isoflurane in 
endothelial cells could affect neuronal cell survival, 
we conducted western blot analysis of anti-apoptosis 
marker and pro-apoptosis marker in neuronal cells 
after incubation with EC-CM. We probed for Bcl-2, an 
anti-apoptosis marker, and Bax, a pro-apoptosis 
marker, in neurons after incubation with EC-CM for 
24 hours (Figure 5). Neuro2A cells, incubated with 
tPA and OGD/R-treated EC-CM, showed decreased 
Bcl-2 and increased Bax protein expression, whereas 
isoflurane pretreated OGD/R + tPA-EC-CM 
abolished these changes in neuronal cells. Neuro2A 
cells incubated with RAP-treated EC-CM, or 
isoflurane + RAP co-treated EC-CM showed 
significant upregulation of Bcl-2, however, Bax 
protein expression was reduced (Figure 5B and 5C, 
n=3,*p< 0.05, **p< 0.01, *** p< 0.001 vs OGD/R + tPA 
group). In addition, Neuro2A cells, incubated with 
MG-132-treated EC-CM or isoflurane + MG-132 
co-treated EC-CM, showed an obvious increase in 
Bcl-2 and suppression of Bax, similar to the pattern 
observed with RAP treatment (Figure 5E and 5F, 
n=3,*p< 0.05, **p< 0.01, *** p< 0.001 vs OGD/R + tPA 
group). These results indicated that neuronal cell 
death was attenuated by isoflurane preconditioned 
EC-CM despite tPA and OGD/R injury. Therefore, we 
suggest that isoflurane could lead to an inhibition in 
tPA-induced neuronal cell death after OGD/R.  
Discussion 
In this study, we investigated the protective 
effects of isoflurane pretreatment on tPA-induced 
endothelial cell damage and neuronal cell death, 
during conditions of OGD/R. Based on our results, 
endothelial cell viability was significantly decreased 
after tPA treatment during conditions of OGD/R, 
compared with only OGD/R injury. Secretion of 
MMPs was activated by tPA treatment and OGD/R 
insult. This process is likely to upregulate the 
LRP/NF-κB/Cox-2 signaling pathway. In addition, 
EC-CM from endothelial cell culture treated with tPA 
and OGD/R had negative effects on neuronal cell 
survival by upregulating pro-apoptotic Bax. 
However, pretreatment with isoflurane enhanced 
endothelial cell viability despite tPA and OGD/R 
injury. Combination of tPA- and OGD/R-induced 
LRP/NF-κB/Cox-2 signaling pathway was 
significantly reduced by isoflurane, RAP, or MG-132. 
Taken together, isoflurane resulted in decreased 
activation of MMP-2 and MMP-9 in endothelial cell 
conditioned media, which might lead to decrease 
neuronal Bax levels even after treatment with tPA and 
OGD/R. Our findings demonstrated that isoflurane 
has preventive effects against tPA- and 
OGD/R-induced cell damage and neuronal 
apoptotic-molecule through inhibition of MMPs 
activation. 
MMPs are a family of zinc-dependent 
endopeptidases associated with the pathogenesis of 
stroke. MMPs degrade extracellular matrix proteins 
for tissue remodeling; however, MMPs play a pivotal 
role in the breakdown of blood vessel barriers which 
leads to hemorrhagic transformation and edema 
formation [17, 18]. These processes have been 
associated with cerebral infarction by activation of 
apoptotic cell death [19]. Specifically, after 
hypoxia-reoxygenation, both MMP-2 and MMP-9 are 
vastly produced [7]. Both MMP-2 and MMP-9 are also 
increased in ischemic brain and in human endothelial 
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cells [7, 20, 21]. Intravenously administrated 
tPA-induced ICH might be involved in MMP 
activation. It was reported that tPA plays an 
important role in MMP-2 and MMP-9 activation [17, 
22] and stimulation of MMPs play important roles in 
the process of excitotoxic anoikis-like cell death for 
neurodegeneration [8, 17]. Also, MMP-9-induced 
breakdown of cell-matrix interaction triggers 
neuronal cell death [8, 17]. As shown by our data, 
after OGD/R injury, which mimics ischemic stroke, 
tPA treatment enhanced MMP-2 and MMP-9 
activations in endothelial cells. Upregulated active 
MMP-2 and MMP-9 in EC-CM might initiate 
upregulating apoptotic-signal in neuronal cells.  
During OGD/R, tPA-induced MMP activation in 
endothelial cell-related intracellular signaling 
pathways may be connected with low-density 
lipoprotein (LDL) receptor-related protein (LRP), 
which consists of a transmembrane and cytoplasmic 
domain, and interacts with various ligands including 
tPA [21, 23]. The previous study demonstrated that 
ischemic stress easily upregulates LRP expression in 
vitro and in vivo studies and increases sensitivity of 
endothelial cells to tPA [4]. Blockade of LRP with RAP 
or anti-LRP and genetic deletion of endogenous tPA 
leads to a reduction of LRP expression in vascular 
structures [24]. Interaction of tPA and LRP regulates 
cerebrovascular tone and permeability of the 
neurovascular units under non-ischemic or ischemic 
condition, and synthesizes MMP-9 [17, 24]. LRP 
downstream signals in endothelial cells can be 
activated by intravascular tPA, which can promote 
activation of NF-κB signaling as shown by our results. 
Several studies also proved that tPA activates NF-κB 
signaling in endothelial cells and NF-κB regulates 
MMP-9 activation [4, 7, 17]. An increase in NF-κB 
activation participates in the induction of an 
inflammatory response and inducible nitric-oxide 
synthase (iNOS). tPA also plays essential roles in 
induction of inflammation and iNOS production after 
cerebral ischemia [25]. OGD/R + tPA-induced Cox-2 
up-regulation was correlated with NF-κB activation 
and these changes could be reversed by inhibition of 
NF-κB translocation to the nucleus using MG-132. 
Therefore, it is speculated that Cox-2 induction might 
be through NF-κB signaling. The previous study 
supported that hypoxia-induced Cox-2 up-regulation 
is mediated by NF-κB p65 in vascular endothelial 
cells, with the mechanisms likely involving binding of 
p65 to the NF-κB -3ʹ site in the Cox-2 upstream 
promoter region [15].  
 
 
Figure 5. Inhibition of endothelial cell conditioned medium (EC-CM) induced pro-apoptotic molecule expression by isoflurane. To examine the 
effect of pretreated isoflurane on neuronal cell survival and death under culture with EC-CM, we performed western blot analysis using Bcl-2 and Bax. (B) The Bcl-2 
protein was significantly upregulated in neuronal cells incubated with EC-CM of isoflurane, RAP, or isoflurane RAP treated groups in the tPA and OGD/R condition. 
(C) In contrast to Bcl-2, the protein levels of Bax was significantly downregulated in neuronal cells incubated with EC-CM of isoflurane, RAP or isoflurane + 
RAP-treated groups in the tPA and OGD/R condition. (E) Bcl-2 protein levels were significantly increased in neuronal cells incubated with EC-CM of isoflurane, 
MG-132, or isoflurane + MG-132-treated groups in the tPA and OGD/R condition. (F) Bax was significantly decreased in neuronal cells incubated with EC-CM of 
isoflurane, MG-132 and isoflurane + MG-132-treated groups in the tPA and OGD/R condition. *p< 0.05, **p< 0.01, ***p< 0.001 vs. OGD/R + tPA group, the one-way 
ANOVA (means ± SEM, OD of Bcl-2 and Bax(n=3)) 
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Studies have demonstrated that isoflurane 
promotes ischemic tolerance, decreases ischemic brain 
injury, and preserves the BBB. Moreover, isoflurane 
may transiently hamper the progression and delay the 
onset of cerebral infarct [26]. In addition, isoflurane 
pretreatment reduces neurological deficits, brain 
edema, and cerebral infarct size after 
ischemia/reperfusion [11]. We determined in the 
previous study that isoflurane post-treatment has a 
protective effect on tPA-exaggerated brain injury [1]; 
however, the protective mechanisms of isoflurane 
against tPA-induced injury after ischemic insult were 
not elucidated. Based on our results, we proved that 
isoflurane preconditioning ameliorates tPA-induced 
injury after OGD/R. Downregulation of OGD/R + 
tPA-triggered LRP/NF-κB/Cox-2 signaling and 
MMP-2 and MMP-9 activation by isoflurane 
pretreatment might be involved in this mechanism, 
which leads to neuronal anti-apoptotic molecule, Bcl-2 
upregulation and pro-apoptotic molecule, Bax 
downregulation. Although we showed changes of 
protein expression in LRP, Cox-2, and NF-κB by 
isoflurane pretreatment, it is not clear that preventive 
effects of isoflurane is from only reduction of these 
signals or blunted endothelial sensitivity against tPA. 
However, these results implicate isoflurane 
preconditioning as having a critical role in vascular 
protection with respect to tPA-exaggerated injury 
after OGD/R. These preventive effects of isoflurane 
preconditioning against tPA-induced injury might 
contribute to the development of a new treatment 
strategy for ischemic stroke. 
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